|
Effect of Probiotics on COVID-19 Infection: A Systematic Review
|
Siavash Hamzeh Pour1    , Shadieh Mohammadi2 , Ehsan Nassireslami 3 |
1- Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
2- Environmental Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
3- Toxin Research center, AJA University of Medical Sciences, Tehran, Iran. , nassireslami@gmail.com |
|
|
Abstract: (592 Views) |
Background and Aim: Scientific evidence has shown that SARS-CoV-2 can infect intestinal epithelial cells and probiotics are capable of inducing immune responses against respiratory viruses. Since there have been no specific guidelines or treatment for the patients with COVID-19, we performed this systematic review of studies to investigate the effect of probiotics on COVID-19 infection.
Materials and Methods: This study included relevant English original articles in the international databases of PubMed and Scopus using the keywords of "severe acute respiratory syndrome", "coronavirus 2", "sars-cov-2", "2019 novel coronavirus", "2019 nCoV", "new coronavirus, COVID-19", "probiotics" and the "combination of these keywords" between the beginning of 2018 and 20 July 2022.
Results: A total of 424 articles were found among which 6 articles met the inclusion criteria for this study. The findings of this study showed that fever, cough, shortness of breath and diarrhea were the main symptoms of the patients with COVID-19. Also, consumption of probiotics using bacterial formula (Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium spp) can be an effective treatment option to reduce the incidence of secondary infections and modulate immunity in the patients with SARS-CoV-2 infection.
Conclusion: It seems that administration of probiotics in order to modulate the intestinal-lung immune axis as an adjunctive treatment can be useful for prevention and management of COVID-19 infection.
|
|
| Keywords: Probiotics, Corona virus, COVID-19, SARS-CoV-2 |
|
|
Full-Text [PDF 513 kb]
(126 Downloads)
|
Type of Study: Review |
Subject:
Microbiology
Received: 2023/03/6 | Accepted: 2023/06/26 | Published: 2024/02/6
|
|
|
|
|
|
|
| References |
1. 1. Agharezaee N, Forouzesh F. SARS-COV-2: history, genetics, and treatment. J Arak Uni Med Sci. 2020;23(5):666-85. [ DOI:10.32598/JAMS.23.COV.5712.2] 2. Mardi P, Shojaeian S, Taherzadeh-Ghahfarokhi N, Molaverdi G, Roudy MA, Salahshour A, et al. SARS-CoV-2 and COVID-19, evidence from a literature review. Tehran Univ Med J. 2021;78(11):712-25. 3. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. [ DOI:10.3390/v12020135] [ PMID] [ ] 4. Danesh F, Ghavidel S. Coronavirus: Scientometrics of 50 Years of Global Scientific Productions. Iran J Med Microbiol. 2020;14(1):1-16. [ DOI:10.30699/ijmm.14.1.1] 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506. [ DOI:10.1016/S0140-6736(20)30183-5] [ PMID] 6. Ahmadikia K, Mahmoudi S, Hassanali F, Keshavarz M, Mirhendi H, Malekzadeh E. A review on the diagnostic approaches of COVID-19 infection; features and limitations. J Isfahan Med School. 2021;39(611): 55-65. 7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223): 507-13. [ DOI:10.1016/S0140-6736(20)30211-7] [ PMID] 8. Ghasemi D, Zarei A, Ardabili MHA, Ashjaei E, Behzadnia MJ. Clinical and epidemiological findings and imaging characteristics of COVID-19 related deaths in Baqiyatallah Hospital in Tehran. J Military Med. 2021;23(3):201-8. 9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280. e8 [ DOI:10.1016/j.cell.2020.02.052] [ PMID] [ ] 10. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192. [ DOI:10.1007/s11684-020-0754-0] [ PMID] [ ] 11. Mahooti M, Miri SM, Abdolalipour E, Ghaemi A. The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment? Microb Pathog. 2020;148:104452. [ DOI:10.1016/j.micpath.2020.104452] [ PMID] [ ] 12. Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. World J Clin Cases. 2021;9(1):8. [ DOI:10.12998/wjcc.v9.i1.8] [ PMID] [ ] 13. Li Q, Cheng F, Xu Q, Su Y, Cai X, Zeng F, et al. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients. Int Immunopharmacol. 2021;95:107531. [ DOI:10.1016/j.intimp.2021.107531] [ PMID] [ ] 14. Din AU, Mazhar M, Waseem M, Ahmad W, Bibi A, Hassan A, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother. 2021;133:110947. [ DOI:10.1016/j.biopha.2020.110947] [ PMID] [ ] 15. d'Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. 2020;7:389. [ DOI:10.3389/fmed.2020.00389] [ PMID] [ ] 16. Anwar F, Altayb HN, Al-Abbasi FA, Al-Malki AL, Kamal MA, Kumar V. Antiviral effects of probiotic metabolites on COVID-19. J Biomol Struct Dyn. 2021;39(11):4175-84. [ DOI:10.1080/07391102.2020.1775123] [ PMID] [ ] 17. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453-7. [ DOI:10.1016/S0140-6736(07)61602-X] [ PMID] 18. Bozkurt HS, Bilen Ö. Oral booster probiotic bifidobacteria in SARS-COV-2 patients. Int J Immunopathol Pharmacol. 2021;35:1-8. [ DOI:10.1177/20587384211059677] [ PMID] [ ] 19. Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral bacteriotherapy in patients with COVID-19: a retrospective cohort study. Front Nutr. 2021;7:613928. [ DOI:10.3389/fnut.2020.613928] [ PMID] [ ] 20. Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, Nieto-Rufino CD, López-Orduña E, Jiménez-Escobar I, et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. [ DOI:10.1080/19490976.2021.2018899] [ PMID] [ ] 21. Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, et al. Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2023;15(3):460-468. [ DOI:10.1007/s12602-021-09858-5] [ PMID] [ ] 22. Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125. [ DOI:10.1111/1751-2980.12851] [ PMID] [ ] 23. Lee N-K, Paik H-D. Prophylactic effects of probiotics on respiratory viruses including COVID-19: A review. Food Sci Biotechnol. 2021;30(6):773-81. [ DOI:10.1007/s10068-021-00913-z] [ PMID] [ ] 24. Darbandi A, Asadi A, Ghanavati R, Afifirad R, Emamie AD, Talebi M. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20. Int J Infect Dis. 2021;105:91-104. [ DOI:10.1016/j.ijid.2021.02.011] [ PMID] [ ] 25. Infusino F, Marazzato M, Mancone M, Fedele F, Mastroianni CM, Severino P, et al. Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review. Nutrients. 2020;12(6):1718. [ DOI:10.3390/nu12061718] [ PMID] [ ] 26. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 2020;69:1010-1018. [ DOI:10.1136/gutjnl-2020-320953] [ ] 27. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020;5(7):745-7. [ DOI:10.1001/jamacardio.2020.1282] [ PMID] 28. Battistoni A, Volpe M. Might renin-angiotensin system blockers play a role in the COVID-19 pandemic? Eur Heart J Cardiovasc Pharmacother. 2020;6(4):248-51. [ DOI:10.1093/ehjcvp/pvaa030] [ PMID] [ ] 29. Kumpitsch C, Koskinen K, Schöpf V, Moissl-Eichinger C. The microbiome of the upper respiratory tract in health and disease. BMC Biol. 2019;17(1):87. [ DOI:10.1186/s12915-019-0703-z] [ PMID] [ ] 30. Li K-j, Chen Z-l, Huang Y, Zhang R, Luan X-q, Lei T-t, et al. Dysbiosis of lower respiratory tract microbiome are associated with inflammation and microbial function variety. Respiratory research. 2019;20(1):1-16. [ DOI:10.1186/s12931-019-1246-0] [ PMID] [ ] 31. Farzaneh S, Tafvizi F. The effect of probiotics on signaling pathways of genes involved in depression. Tehran Univ Med J. 2018;76(3):155-61. 32. Ziaeifar E, Goodarzi A, Saki N. The role of microbiota, probiotics and prebiotics in dermatology. Journal of Dermatology and Cosmetic. 2019;10(1):44-51. 33. Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol. 2019;12(4):843-50. [ DOI:10.1038/s41385-019-0160-6] [ PMID] 34. Bradley KC, Finsterbusch K, Schnepf D, Crotta S, Llorian M, Davidson S, et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 2019;28(1):245-56. e4. [ DOI:10.1016/j.celrep.2019.05.105] [ PMID] 35. Cait A, Hughes M, Antignano F, Cait J, Dimitriu P, Maas K, et al. Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids. Mucosal Immunol. 2018;11(3):785-95. [ DOI:10.1038/mi.2017.75] [ PMID] 36. Di Renzo L, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur Rev Med Pharmacol Sci. 2020;24(8):4062-4063. 37. Zeng J, Wang C-T, Zhang F-S, Qi F, Wang S-F, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016;42(6):1018-28. [ DOI:10.1007/s00134-016-4303-x] [ PMID] 38. Zolnikova O, Komkova I, Potskherashvili N, Trukhmanov A, Ivashkin V. Application of probiotics for acute respiratory tract infections. Italian Journal of Medicine. 2018;12(1):32-8. [ DOI:10.4081/itjm.2018.931] 39. Feng Z, Wang Y, Qi W. The small intestine, an underestimated site of SARS-CoV-2 infection: from red queen effect to probiotics. Preprints 2020, 2020030161. [ DOI:10.20944/preprints202003.0161.v1] 40. Louca P, Murray B, Klaser K, Graham MS, Mazidi M, Leeming ER, et al. Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app. BMJ Nutr Prev Health. 2021;4(1):149-57. [ DOI:10.1136/bmjnph-2021-000250] [ PMID] [ ] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
